In this clinically relevant model, luciferase-expressing human GBM cells would be implanted intracranially, and treatment efficacy will be evaluated based on the primary endpoint of overall survival, supported by secondary endpoints such as serial bioluminescence imaging for tumor growth monitoring and histopathological analysis of excised tumors for proliferative index (Ki-67), apoptosis (Cleaved Caspase-3), and target modulation (p-FAK/p-Akt). The gene discussed is PTK2; the disease is neoplasm.